{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:19:44Z","timestamp":1790936384693,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report the outcomes after reduced-intensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n = 41; high-grade NHL [HG-NHL], n = 37; mantle cell lymphoma [MCL], n = 10). Thirty-seven patients had previously received autografts, and 21 were in complete remission (CR) at transplantation. Conditioning therapy consisted of alemtuzumab, fludarabine, and melphalan. Sixty-five patients received peripheral blood stem cells (PBSCs) from HLA-identical siblings, and 23 received bone marrow (BM) from matched unrelated donors. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporin A. Grade III-IV acute GVHD developed in 4 patients, and chronic GVHD developed in 6 patients. With a median follow-up of 36 months (range, 18-60 months), the actuarial overall survival (OS) rates at 3 years were 34% for HG-NHL, 60% for MCL, and 73% for LG-NHL (P &amp;lt; .001). The 100-day and 3-year transplant-related mortality (TRM) rates for patients with LG-NHL were 2% and 11%, respectively, and were better (P = .01) than they were for patients with HG-NHL (27% and 38%, respectively). The actuarial current progression-free survival (PFS) rate at 3 years, including the rate for patients who achieved remission after donor lymphocyte infusion (DLI) for progression, was 65% for LG-NHL, 50% for MCL, and 34% for HG-NHL (P = .002). Twenty-one patients underwent DLI for matched related donor (MD)-persistent disease or relapse, and 15 underwent DLI for mixed hematopoietic chimerism. Patients who experienced relapses of LG-NHL and chronic lymphocytic leukemia (CLL) achieved excellent PFS with extremely low TRM and GVHD, even when matched related donors were unavailable. (Blood. 2004;104:3865-3871)<\/jats:p>","DOI":"10.1182\/blood-2004-03-1105","type":"journal-article","created":{"date-parts":[[2004,8,10]],"date-time":"2004-08-10T21:13:08Z","timestamp":1092172388000},"page":"3865-3871","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":246,"title":["Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"104","author":[{"given":"Emma","family":"Morris","sequence":"first","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Thomson","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Mahendra","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Milligan","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme Murray","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Parker","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Schey","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Chopra","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hatton","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Tighe","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hunter","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Peggs","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Linch","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Goldstone","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mackinnon","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, University College London Hospitals; the Department of Immunology, Imperial College, London; and the UK Collaborative Group, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217573203200_REF1","doi-asserted-by":"crossref","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol.1998;16: 2780-2795.","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"2020021217573203200_REF2","doi-asserted-by":"crossref","unstructured":"Gribben JG, Goldstone A, Linch DC, et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol.1989;7: 1621-1629.","DOI":"10.1200\/JCO.1989.7.11.1621"},{"key":"2020021217573203200_REF3","doi-asserted-by":"crossref","unstructured":"Philip T, Armitage JO, Spitzer G, et al. High dose therapy and ABMT after failure of conventional chemotherapy in adults with intermediate-grade or high grade non-Hodgkin's lymphoma. N Engl J Med.1987;316: 1493-1498.","DOI":"10.1056\/NEJM198706113162401"},{"key":"2020021217573203200_REF4","doi-asserted-by":"crossref","unstructured":"Chopra R, Goldstone A, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case controlled analysis of European Bone Marrow Transplant Group registry data. J Clin Oncol.1992;10: 1690-1695.","DOI":"10.1200\/JCO.1992.10.11.1690"},{"key":"2020021217573203200_REF5","doi-asserted-by":"crossref","unstructured":"Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood.1997;90: 4201-4205.","DOI":"10.1182\/blood.V90.10.4201"},{"key":"2020021217573203200_REF6","doi-asserted-by":"crossref","unstructured":"van Besien KW, Khouri IF, Giralt SA, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol.1995;13: 1096-1102.","DOI":"10.1200\/JCO.1995.13.5.1096"},{"key":"2020021217573203200_REF7","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood.2001;98: 3595-3599.","DOI":"10.1182\/blood.V98.13.3595"},{"key":"2020021217573203200_REF8","doi-asserted-by":"crossref","unstructured":"Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol.2003;21: 4407-4412.","DOI":"10.1200\/JCO.2003.05.501"},{"key":"2020021217573203200_REF9","doi-asserted-by":"crossref","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood.2001;97: 3390-3400.","DOI":"10.1182\/blood.V97.11.3390"},{"key":"2020021217573203200_REF10","doi-asserted-by":"crossref","unstructured":"Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol.2000;18: 3918-3924.","DOI":"10.1200\/JCO.2000.18.23.3918"},{"key":"2020021217573203200_REF11","doi-asserted-by":"crossref","unstructured":"Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood.2002;99: 75-82.","DOI":"10.1182\/blood.V99.1.75"},{"key":"2020021217573203200_REF12","unstructured":"Horning S. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol.1993;20: 75-88."},{"key":"2020021217573203200_REF13","doi-asserted-by":"crossref","unstructured":"Kottaridis PD, Milligan D, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood.2000;96: 2419-2425.","DOI":"10.1182\/blood.V96.7.2419"},{"key":"2020021217573203200_REF14","doi-asserted-by":"crossref","unstructured":"Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood.2002;99: 1071-1078.","DOI":"10.1182\/blood.V99.3.1071"},{"key":"2020021217573203200_REF15","doi-asserted-by":"crossref","unstructured":"Faulkner RD, Craddock C, Byrne JL, et al. BEAM-Campath reduced intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity and survival in 65 patients. Blood.2004;103: 428-434.","DOI":"10.1182\/blood-2003-05-1406"},{"key":"2020021217573203200_REF16","doi-asserted-by":"crossref","unstructured":"Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood.2003;102: 404-406.","DOI":"10.1182\/blood-2002-09-2687"},{"key":"2020021217573203200_REF17","doi-asserted-by":"crossref","unstructured":"Peggs KS, Thomson K, Hart DP, et al. Dose escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood.2004;103: 1548-1556.","DOI":"10.1182\/blood-2003-05-1513"},{"key":"2020021217573203200_REF18","doi-asserted-by":"crossref","unstructured":"Hurley CK, Wade JA, Oudshoorn M, et al. A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors: Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hum Immunol.1999;60: 347-360.","DOI":"10.1016\/S0198-8859(98)00129-3"},{"key":"2020021217573203200_REF19","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant.1995;15: 825-828."},{"key":"2020021217573203200_REF20","doi-asserted-by":"crossref","unstructured":"Mackinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood.1994;83: 3409-3416.","DOI":"10.1182\/blood.V83.11.3409.3409"},{"key":"2020021217573203200_REF21","doi-asserted-by":"crossref","unstructured":"Cheson B, Bennett J, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood.1996;87: 4990-4997.","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"2020021217573203200_REF22","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning S, Coiffier B, et al. Report of an International Workshop to Standardize Response Criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol.1999;17: 1244-1253.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"2020021217573203200_REF23","doi-asserted-by":"crossref","unstructured":"Bearman SI, Appelbaum F, Back A, et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol.1989;7: 1288-1294.","DOI":"10.1200\/JCO.1989.7.9.1288"},{"key":"2020021217573203200_REF24","doi-asserted-by":"crossref","unstructured":"Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant.2003;9: 257-265.","DOI":"10.1053\/bbmt.2003.50009"},{"key":"2020021217573203200_REF25","doi-asserted-by":"crossref","unstructured":"Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol.1995;13: 588-595.","DOI":"10.1200\/JCO.1995.13.3.588"},{"key":"2020021217573203200_REF26","doi-asserted-by":"crossref","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, et al. Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation: chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood.2002;100: 4310-4316.","DOI":"10.1182\/blood-2001-11-0107"},{"key":"2020021217573203200_REF27","doi-asserted-by":"crossref","unstructured":"Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol.1986;1986: 1470-1480.","DOI":"10.1200\/JCO.1986.4.10.1470"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/13\/3865\/1704490\/zh802404003865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/13\/3865\/1704490\/zh802404003865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T18:55:37Z","timestamp":1581533737000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/13\/3865\/18981\/Outcomes-after-alemtuzumabcontaining"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,15]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2004,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-03-1105","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,15]]}}}